1 / 4

The Research Question

This study examines the effectiveness of antidepressants in treating depressive symptoms in patients with cardiometabolic diseases and highlights the need for further investigation in this area. Findings suggest that continuous antidepressant treatment does not significantly improve outcomes compared to no treatment, while intermittent treatment may even be detrimental.

smontoya
Download Presentation

The Research Question

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Research Question Use of Antidepressants in Patients with Depression and Cardiometabolic DiseaseBhautesh Jani, David Purves, Sarah Barry, Colin McCowan, Jonathan Cavanagh, Frances Mair • Do antidepressants work in the long run in treatment of depressive symptoms in patients with cardiometabolic diseases? • Why this is important? • Depression is very common in Cardiometabolic disease (CHD, Diabetes, Stroke) • Depression increases the risk of complications- deaths, vascular events, compliance, quality of life

  2. What the Researchers Did • Method- retrospective cohort review of data in routine practice • N=7080 patients with cardiometabolic disease had HADS-D (Hospital Anxiety and Depression Scale) at baseline and 12 months follow-up • Compared mean change in HADS-D for antidepressants prescribed vs. untreated • Compared rate of remission (HADS-D>8)

  3. What the Researchers Found • Mean change in HADS-D at 12 months (Efficacy) • No difference between untreated and continuously treated group • Intermittently treated group did worse than untreated group • Rate of remission at 12 months(Effectiveness) • No difference in odds of remission between untreated and continuously treated group • Intermittently treated group had lower odds of remission

  4. What This Means for Clinical Practice • No significant improvement in follow-up HADS-D or in odds of remission at 12 months with antidepressants • Baseline HADS-D severity did not change the trend in results • The role of antidepressants in treatment of depression in cardiometabolic disease needs further scrutiny

More Related